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1INTRODUCTION
Adenocarcinoma of stomach , so called “Captain of men of death” was
the leading cause of cancer related deaths through the most of the 20 th
century and as on now ranking second only next to lung cancer.
Even though surgical resection is the mainstay treatment for early
gastric cancer, most of the patients present to us in advanced stages
where adjuvant chemoradiation comes into play.
Survival of patients with advanced resectable/non resectable gastric
cancer treated with chemotherapy still remains poor. So the role of novel
therapies is warranted.
Her 2/neu ( human epidermal growth factor receptor 2) also called as
erbB2 /cd340/p185 is a protein encoded by gene ERBB2, a member of
EFGR/erbB family. Amplification or over expression of HER 2/NEU
which acts as a proto oncogene has been demonstrated to play an
important role as a bio marker and target of therapy in breast cancer .
It has been demonstrated in recent western clinical trials , over
expression of the same in gastric cancer too. But the frequency of
expression differs in each geographical area and incidence of her 2 /neu
in gastric cancer in south Indian population is not clear. Western  studies
2indicate poor prognosis and poor response to chemotherapy   in
HER2/NEU over expressed cases of gastric cancer, but as on now, no
study is clear in India.
Trastuzumab is a monoclonal antibody which specifically targets
HER2 protein by directly binding to extracellular domain of receptor
and successfully used for breast cancer patients ,but not yet been tried in
India for gastric cancer patients. This study may pave way for the
introduction of trastuzumab in treating  patients with advanced gastric
malignancies and thereby enhance survival rates and improve the quality
of life of those patients justifying the cost benefits.
Since most of the patients coming to our hospital are poor and
cannot afford costly drugs, the justification to start a treatment is
warranted and this study may provide a justification.
3AIMS AND OBJECTIVES
1. To know the incidence of HER2/NEU over expression in gastric
cancer in our locality.
2. To study the staging , operability and prognosis of gastric cancer
in relation to HER2/NEU expression
3. To study the aggressiveness and histology of gastric cancer in
relation to HER2/NEU expression.
4. To study the HER2/NEU expression based on locality of tumours.
4HISTORY OF GASTRIC CANCER
The long history of gastric cancer begins with the mentioning in
1600 BC according to ebers papyrus and also in the Hipprocrates reports
around second century AD.
 Around 980 AD, Avicenna of Arabia, mentioned about stomach
cancer in his encyclopedia. After that during the medieval period, there
was no progress in the knowledge of gastric cancer except for the
purgatives and blood letting according to the black bile theory of
Hippocratic period, till in 1835, Cruvelheir  described benign and
malignant gastric ulcer.
GASTRIC CANCER AND NAPOLEAN BONAPARTE:
History says that the French emperor Napoleon Bonaparte could
have suffered a schirrous carcinoma of stomach following a familial
history as reported by Dr.Antonmarchi, his family physician. he exiled
to St. Helena, an island in  Atlantic Ocean, following defeat in the war
of waterloo.  During his St. Helena exile,In 1819 he began to suffer from
Repeated episodes of fever, abdomen ache, hiccoughs, and vomiting.
His treatment was frequent large doses of purgatives and blood letting
and his symptoms worsened around September 1820: he vomited daily
and altered bowel habits
5epigastric pain, fatigue and fever. In 1821, he vomited coffee-ground-
vomitus, and had severe hiccoughs and tachycardia  and was in delirium
. .During then he told Dr. Antonmarchi, “ . . . I desire you operate me
and  examine my stomach and make a detailed report and you should
give to my son.” He knew he had a gastric problem because it was the
cause of death of his father and family relatives. In  1821, may 5, in the
early morning he died following a bout of haematemesis and melena and
hypovolemic shock.
FIG.NAPOLEAN BONAPARTE AND HIS EPIGASTRIC PAIN.
Eight physicians attended the autopsy. Dr. Francesco
Antonmarchi was his friend rest other seven were British.  The most
6detailed report by Antonmarchi,  an anatomopathologist of  University
of Pisa:
“. .. the gastric volume was smaller, its anterior surface is normal
and on the right side there is a close adhesion with the inferior left liver
and perforated in the center. The perforation was sealed by the liver
adhesion. On opening stomach,over Greater curvature its capacity
appeared filled with a Coffee coloured liquid. The interiorof the stomach
was a cancerous ulcer whose center was near the lesser curve and the
induration spread from the cardiac to pylorus, with a scirrhous
thickening of the wall.”
Since tissue microscopy was not developed by then, autopsy
diagnosis relied upon The morphology. Nevertheless the reports clearly
show that Napoleon had scirrhous gastric carcinoma probably with
gastric outlet obstruction which manifested clinically as intractable
vomiting and hiccoughs Previously, for many years, the emperor had
suffered vague abdominal symptoms, perhaps due to chronic gastritis
which preceded his familial gastric cancer.
In the year 1874-76, Billroth described  distal gastric resection
with anastamosis of stomach and duodenum type 1 and to the jejunum
7type 2. In 1879, Pean was the first do gastric resection for malignancy,
even though the patient died on the fifth post operative day.
In 1881, Billroth did a successful resection. In 1881, Wolfler &
Nicolodani did antecolic gastrojejunostomy. In  1883, Courvoisier
performed retrocolic gastrojejunostomy. In 1893he advised
jejunojeunostomy along with GJ. In 1898 Schlatter for the first time
performed total gastrectomy. In 1907 wendel resected  oesophagus &
stomach for malignancy.
 In 1930, Polya performed anastamosis of entire opening of
stomach with jejunum(santorio 2005)
In 1981, Longmire did radical treatment for stomach cancer. After
that there has been immense progress recently, though total/subtotal
gastrectomy with D 2 lymphadenectomy stillremains the standard of
care.
In1982, Robin warren and Barry Marshall found H.pylori was
responsible for benign and malignant gastric ulcers. In 1978, Stanley
cohen discovered Epidermal  growth factor, the first receptor tyrosine
kinase and neu oncogene was discovered @ the Massachusetts institute
of technology in 1882-84.
8In 1998, therapy targeted against HER2/NEU was approved for
breast carcinoma, only in the recent years, link between HER 2/neu over
expression & gastric cancer has been studied.
 EMBRYOLOGY OF STOMACH
Stomach, esophagus and duodenum are developed by the
elongation of the foregut, embryologically around 4th or  5th week.
Initially at the level of c3- c5,  thereafter following truncal growth,
reaches the T10-L3 level, its normal final position around 10 th week,
following which a clock wise rotation of 90 degrees occursaround
longitudinal axis, hence dorsal midline forms the greater curvature and
ventral becomes lesser curvature.
 Fundus outgrowth occurs at eighth month and gastric rugae
makes its appearance by eigth week  and muscularis develops by 8-14
weeks and glandular pits appear all over the stomach by 10th week. By
11th and 12th week, parietal and chief cells are formed respectively.
9SURGICAL ANATOMY
MORPHOLOGY OF STOMACH:
Stomach begins from gastro-esophageal junction, 2-3 cms below
diaphragm and ends in pyloro-duodenic junction and comprises of
1. CARDIA:,where the esophagus joins and forms the OG junction.
2. FUNDUS: part of stomach above cardia
3. BODY: between fundus and pylorus
4. PYLORUS: divide into 2 parts a. Antrum- the proximal most part
which starts at the level of angular notch at the lesser curvature
and b.pyloric canal.
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 The line of demarcation of the pylorus and duodenum is considered to
be the pre-pyloric vein of Mayo.
Surgically, stomach is divided into 2 by the line joining the first
branch of left gastric artery to the midpoint of gastroepiploic vessels as
1. Proximal gastric unit: comprising the og junction, fundus and
body
2. Distal gastric unit: consisting of pylorus and first part of
duodenum.
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Anatomy  of  GASTRO-ESOPHAGEAL JUNCTION:
 The length of the abdominal oesophagus varies from 0.5-2.5 cm
and its related anteriorly to posterior surface of liver and posteriorly to
the diaphragm and aorta .
Caudate lobe lies to his right and fundus to the left of it.
According to the endoscopist, GE junction lies at the demarcation of
mucosa from pale to pink, but to the surgeon its inside the stomach next
to oesophageal stump penetrating the diaphragm where it is lined by
endo abdominal fascia.
ANATOMY OF GASTRODUODENAL JUNCTION:
        The duodenum anchors the pyloric antrum. Hence mucosa lining is
of 3 types:
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1. Antral
2. Transitional
3. Jejunal
It is anterior to IVC & not fixed to anatomic entities of posterior
abdominal wall.
PERITONEAL REFLECTIONS:
The peritoneum covers the anterior  and posterior portions of
stomach.lesser omentum extends from liver hilum to stomach and
duodenum via hepatogastric and hepatoduodenal ligaments.
Proximally it encircles the stomach and continues as
gastrophrenic and gastrosplenic ligament, distally it forms greater
13
omentum descending and ascending again to reach the pancreas.
GASTROESOPHAGEAL WALL:
Stomach wall consists of
1. Mucosa – innermost layer comprising of columnar epithelium of
glands
   Glandular epithelium is classified into
a. digestive /exocrine cells:
        1. parietal cells
        2. chief cells
14
        3. mucus secreting cells
 b. gastric function/ endocrine cells:
         1. G cells secreting gastrin
         2.D cells secreting somatostatin.
 Cardia contains mostly mucus cells. Body contains mostly parietal and
chief cells. Parietal cells are absent in fundus and antrum. G cells are
present in large quantities in antrum.
2. sub mucous  layer:
         Strongest and rich vascular supplied layer by anastamotic vessels
and meissner’s plexus of autonomic nerves
3.muscular layer: comprising of
                  a. outer longitudinal layer
                  b. middle and
                  c. inner circular layer
4.peritoneum forming the serosal surface.
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BLOOD SUPPLY:
STOMACH IS SUPPLIED BY 4 MAJOR ARTERIES.
1. left gastric artery- largest                  along the lesser
2. right gastric artery                              curvature
3. right gastroepiploic artery                   along the greater
4. left gastrepploic artery                       curvature
Also by 5. Inferior phrenic artery and
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6. short gastric arteries from splenic artery.
 Veins are corresponding to arteries.
Lymphatic drainage:
Superior part of lesser curvature drains to nodes along left gastric
and paracardiac nodes. Inferior antral segment drains intosuprapyloric
nodes
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It is divided into 4 LEVELS:
LEVEL   drainage OF subpyloric and omental nodes
LEVEL  II drainage of  pancreatic and splenic nodes
LEVEL  III  drainage of superior gastric nodes
LEVEL  IV  drainage of  supra pyloric nodes
NERVE SUPPLY:
1. PARASYMPATHETIC SUPPLY  is via vagus nerve.
Left vagus nerve is anterior and supplies left lobe of liver and continues
as anterior nerve of latarjet
Right vagus nevr is posterior which forms the celiac plexus and
continues as the posterior nerve of latarjet
2. sympathetic supply is from T5-10 which forms celiac ganglion and
supplies to stomach via meissner’s and auerbach’s plexus
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PHYSIOLOGY:
GASTRIC MUCOSA  is constantly in contact with secreted acid
and foreign objects such as food and hence more prone for injury. Its is
protected from injury through the following mechanisms
1. increased blood flow helps in rapid turnover of epithelium and buffers
the effect of acid in the lumen
2. bicarbonate acts as a acid buffer
3.mucus creates a barrier between contents and epithelium.
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4.increased blood flow by prostaglandins
5.bombesin increases prostaglandin secretion.
Acid secretion is mediated by 3 phases:
1.cephalic mediated by vagus
2.gastric maintained by gastric distension and luminal peptides
3. intestinal phase which is an inhibitory phase.
It is maintained at low basal rate during fasting by D cells secreting
somatostatin which inhibits acid secretion
Pepsinogen and its Secretion
 Chief cells  secrete mainly pepsinogens, stored by  granules of
zymogen. These are the precursors of  pepsins (proteases) present in
gastric secretions. As soon as secreted, pepsinogen I is activate into the
active protease pepsin by acidic medium.
It  is an endopeptidase initiating  protein digestion into peptides
and polypeptides. A pH 1.5–2.5 is essential  and  pH  of above 5.4 is
inactivated. Its release is effected  by vagal stimulation .Pepsinogen
may also  be released during periods of hypoglycaemia and prolonged
increased intracranial pressure.
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GASTRIN:
Gastrin causes
1.   acid secretion by parietal cells
2.  secretion of intrinsic factor
3. Increased mitotis of stomach and small bowel mucosa
4. LES contraction.
5. insulin, glucagon  release.
6. stimulation of pancreas also bile flow
7.Small bowel secretion
8.increased peristalsis
9. gastrocolic reflex
SOMATOSTATIN:
Somatostatin inhibits the release of growth hormone  of pituitary
gland.In  stomach it is present  in the pyloric and oxyntic cell mucosal
zones and  not in thecardiac zone.it not only suppresses  the secretion of
growth hormone, it  inhibits  other pituitary and extrapituitary
secretions. Itsuppresses insulin along with  exocrine secretions of
pancreas,  secretin by the intestine, and secretion of gastrin, HCl and
pepsin by the stomach. Somatostatin suppresses gastric acid secretion by
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direct action on the parietal cells . Thus in acidic  pH, it  inhibits gastrin
secretion through a negative feedback loop .
Other  Hormones
Encephalin
Are considered as endogenous . consists of :, endorphin and
enkephalin. It is  found everywhere the alimentary canal, it is highest  in
pyloric antrum.
Galanin
Galanin  regulates  gastrointestinal motility. It is usually found along
with VIP-containing nerves.
Neurotensin
 Ileal  mucosa secretes this hormone. It inhibits gastric acid and pepsin
secretion and delays gastric emptying, which leads controlled chime
release to duodenum
22
REVIEW OF LITERATURE
GASTRIC CARCINOMA
Epidemiology
 Carcinoma stomach  was the commonest cancer worldwide in the
late 20 th century  and is now next to  lung cancer among cancer related
deaths. Gastric  carcinoma  incidence varies geographically, with
highest rates in Japan  and Europe. Rates are  rising in India.
 In Gastric cancer male preponderance is seen and sex ratio is 2:1
,  age also increases the incidence progressively, and highest incidence
is during the seventh decade. Study on people who migrated  from  high
incidence areas to low incidence areas suggest that environmental
exposure , cultural or genetic factor also predispose to gastric cancer.
There is change in trend in the anatomic location of gastric cancer from
distal gastric unit to proximal gastric unit in  past 30 years. The
carcinoma of  OG junction is increasing , whereas  in other  area s has
decreased.
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Risk Factors
Studies on diet  reveal the following risk factors:
1.   animal protein and fat low diet
2,  complex carbohydrates rich diet.
3. meats and fish which are salted.
4.with high levels of nitrates and H. pylori in drinking water .
Diets protective for gastric carcinoma are the consumption of :
1. greeneries,
2. citrus like lemon
3. fiber rich  breads .
Vitamin C and ?-carotene available  in fruits  has  antioxidants, and
ascorbic acid prevents conversion of nitrates to nitrites , a well known
risk factor
The presence of IgG antibodies against H. pylori  correlates with
the incidence, mortality  of stomach cancer. In H.pylori infection with
the cagA strain,  mucosal inflammation is more compared to cagA-
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negative strains and risk for gastric cancer is more . Interleukin-1 gene
cluster polymorphisms are risk factors for hypochlorhydria and gastric
cancer.
The link between prior stomach  operation  for benign disease and
gastric cancer  was reported by Balfour in 1922. Atrophic   gastritis
along with gastritis cystica profunda is  associated with dysplasia in 5%
of patients, for which endoscopy is indicatedas surveillance
 Pernicious anemia ,  autoimmune inflammation  of  oxyntic
mucosa  raises  gastric cancer risk, like  other  chronic inflammatory
states.. Achlorhydria is pathognomonic due to destruction of chief and
parietal cells resulting in atrophiuc mucosa , antral and intestinal
metaplasia.
 Hyperplastic polyps,which  are benign are increased risk for
gastric cancer because of their occurrence in  gastritis.
Adenomatous polyps are at higher risk for malignancy.
Pedunculated     lesions are removed endoscopically which is adequate if
margeins are negative but  If a sessile and large >2 cm polyp has a
malignant focus, surgery is required.
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Genetic abnormalities with  association with gastric carcinoma
are:
1.  oncogene activation
2.  tumor suppressor genes are inactivated
3. cellular adhesion reduction,
4. telomerase reactivation, and
5. presence of microsatellite instability.
The c-met proto-oncogene, k-sam and c-erbB(HER2/NEU) are
overexpressed oncogenes. The p53 and p16  are inactivated  stomach
cancers. Mutations of  Adenomatous  polyposis coli  gene are  common
in intestinal-type stomach cancers.
Pathology
Adeno carcinomas are s95% of all malignant stomach  neoplasms
are . Other histologic types include
1.squamous cell carcinoma,
2.adenoacanthoma,
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3. carcinoid tumors,
4. GI stromal tumors, and
5. lymphoma.
 The Borrmann classification system  developed in 1926 is for
endoscopic findings. It  divides gastric  into 5 types depending on
macroscopic appearance of lesions.
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Linitis plastica is  type 4 carcinoma as it involves entire thickness of
stomach. The  histologic classification system  by Borders in 1942
classified gastric carcinomas based on
1. cellular differentiation degree
2.  morphology, and
Ranging  from 1 (WDC) to 4 (anaplastic).
 Lauren in 1965 classified  gastric adenocarcinoma into intestinal
or diffuse types based on histology . The intestinal variant occurs
fromprecancerous condition such as atrophic mucosa  or intestinal
metaplasia. Men are most commonly affected than women..
INTESTINAL DIFFUSE
Environmental Familial
Gastric atrophy, intestinal
metaplasia
Blood type A
Men >women Women >men
Increasing incidence with age Younger age group
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Gland formation Poorly differentiated, signet ring
cells
Hematogenous spread Transmural/lymphatic spread
Microsatellite instability
APC gene mutations
Decreased E-cadherin
p53, p16 inactivation p53, p16 inactivation
The diffuse gastric carcinoma is:
1. poorly differentiated,
2. no  gland formation, and
3.presence of  signet ring cells.
4. spread submucosally
5.  less inflammatory infiltration, and
6.metastasizes early
7. association with blood type A and familial occurrences.
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American Joint Cancer Commission (AJCC) tumor node metastases
(TNM) staging system.
CATEGORY CRITERIA
Primary Tumor (T)
TX Primary tumor not assessible
T0 No evidence of primary tumor
Tis Carcinoma in situ: intraepithelial tumor
without invasion of the lamina propria
T1 Tumor invades lamina propria or
muscularis mucosae OR SUBMUCOSA
T2 Tumor invades MUSCULARIS
PROPRIA
T2 Tumor invades muscularis propria
T3 Tumor penetrates subserosal connective
tissue without invasion of visceral
peritoneum or adjacent structures
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CATEGORY CRITERIA
T4a
T4b
Tumor invades serosa
Tumour involves adjacent structures
Regional Lymph Nodes (N)
NX Regional lymph node(s) cannot be
assessed
N0 No regional lymph node metastasis
N1 Metastasis in 1 to 2 regional lymph nodes
N2 Metastasis in 3 to 6 regional lymph nodes
N3 Metastasis in more than 7 regional lymph
nodes
Distant Metastasis (M)
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
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TABLE 3 Anatomic stage/prognostic groups, gastric cancer
Stage 0 Tis N0 M0
Stage IA T1 N0 M0
Stage IB
 T2 N0 M0
T1 N1 M0
Stage 2A
T3 N0 M0
T2 N1 M0
T1 N2 M0
Stage 2B
 T4a N0 M0/T3 N1 M0
T2 N2 M0/T1 N3 M0
Stage 3A T4a N1 M0 /T3 N2 M0
T2 N3 M0
Stage3B- T4b N0 or N1 M0
T4a N2 M0
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T3 N3 M0
Stage3C- T4b N2 or N3 M0
T4a N3 M0
Stage 4- Any T Any N M1
Clinical  Presentation
Gastric adenocarcinoma uaually presents at late stages in view of
vague symptoms like epigastric discomfort and indigestion, which
usually diagnosed as gastritis,treated symptomatically. Advanced
disease  presents with  loss of weight and appetite, fatigue, or vomiting.
Gastroesophageal  junction tumors  present with swallowing
difficulty,  antral malignancy  present as  GOO gastric outlet
obstruction. Linitis plastica  leads to early satiety
 Patients  come  with following  a palpable epigastric  mass,
supraclavicular node (Virchow's) or periumbilical aka Sister Mary
Joseph's lymph node, pouch of doughlas deposits (Blummer's shelf), or
ovarian mass aka Krukenberg's tumor.
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Preoperative Evaluation
When stomach cancer diagnosis is considered , flexible
oesophagogastroduodeno endoscopy is the investigation of choice.
During endoscopy, multiple biopsy samples (six  or more) should be
taken around  ulcer  . When multiple biopsy specimens are taken ,
sensitivity  of  procedure nears 98%.. Also , the size, location, and tumor
morphology is noted. In selected patients with advanced stages,
esophagogastroduodenoscopy plays a palliative role through  laser
ablation, dilation, or tumor stenting.
 Endo usg is used to stage early gastric cancers.After confirmation
of gastric cancer,  CBC, RFT, AND LFT, coagulation profile, CXR, and
CT scan  abdomen. In women, a pelvic CT scan or ultrasound is MUST.
CT chest is needed for proximal gastric cancers. CT  detects metastasis
and malignant ascites. The major limitations of CT are  detection of
small (<5 mm) mets in the surface of  liver or on peritoneum.Diagnostic
laparoscopy is  the next logical step in  evaluation. Laparoscopy can
detect metastasis in 20% to 40% of patients judged  as  eligible for
curative resection.
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Subjecting the diagnostic peritoneal lavage fluid for cytology may
reveal carcinamatous deposits, just like  with macroscopic stage IV
disease.
The term R status  by Hermanek in 1994  describes the tumor
status following resection.
R0 - microscopically margin-negative resection
R1  macroscopic margin free, but microscopic margins positive
for tumor.
R2 indicates gross residual disease.
Table 47-9  -- Grouping of Regional Lymph Nodes by
Location of Primary Tumor According to  Japanese Classification
of Gastric Carcinoma
LOCATION OF PRIMARY
TUMOR IN STOMACH
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LYMPH NODE
STATION (NO.) DESCRIPTION
Upper
Third
Middle
Third
Lower
Third
1 Right paracardial 1 1 2
2 Left paracardial 1 3 M
3 Lesser curvature 1 1 1
4sa Short gastric 1 3 M
4sb Left gastroepiploic 1 1 3
4d Right
gastroepiploic
2 1 1
5 Suprapyloric 3 1 1
6 Infrapyloric 3 1 1
7 Left gastric artery 2 2 2
8a Anterior comm.
Hepatic
2 2 2
8p Posterior comm. 3 3 3
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LOCATION OF PRIMARY
TUMOR IN STOMACH
LYMPH NODE
STATION (NO.) DESCRIPTION
Upper
Third
Middle
Third
Lower
Third
Hepatic
9 Celiac artery 2 2 2
10 Splenic hilum 2 3 M
11p Proximal splenic 2 2 2
11d Distal splenic 2 3 M
12a Left
hepatoduodenal
3 2 2
12b,p Posterior
hepatoduodenal
3 3 3
13 Retropancreatic M 3 3
14v Superior
mesenteric vein
M 3 2
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LOCATION OF PRIMARY
TUMOR IN STOMACH
LYMPH NODE
STATION (NO.) DESCRIPTION
Upper
Third
Middle
Third
Lower
Third
14a Superior
mesenteric artery
M M M
15 Middle colic M M M
16al Aortic hiatus 3 M M
16a2,b1 Para-aortic, middle M 3 3
16b2 Para-aortic, caudal M M M
M, lymph nodes regarded as distant metastasis.
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Surgical Treatment
The  surgical management of gastric cancer is tailored according
to the spread and location of disease. Aggressive  surgical resection is
justified only in absence of metastasis. AsJ Gastric  tumors have
extensive intramural spread,  resection margins should be  at least 6 cm
from the tumor mass
 Proximal  gastric unit  comprises for 30% to 50% of all gastric
cancers. For proximal lesions, either total gastrectomy or
oesophagogastrectomy done
Fig,subtotal gastrectomy with roux –en-y gaso jejunostomy with
jejunojejunostomy
39
Distal gastric unit  account for about 35% of all gastric cancers.
Subtotal  gastrectomy is done for  whom a negative margin resection is
achieved with same 6 cms margin.
The role of extended lymphadenectomy  are best described by the
Japanese, The groupings, according to primary site,
1.  D1 resection means  complete removal of group 1  nodes,
2. D2  dissection -group 1 and 2,
3. D3 resection - D2 resection and removal of para-aortic lymph nodes.
40
pic 1. Total gastrectomy
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Splenectomy is now not recommended for  gastrectomy for
cancer because increased morbidity and mortality
Extended D2 lymph node dissection is routine procedure in Japan
, proved a survival benefit over  D1 dissections] Extended lymph node
dissections for stomach cancer  is  performed at higher  centers as a part
of clinical trial .
Palliative Treatment
Nearly half of patients present with stage 4 disease, necessitating
palliative surgery.Surgical palliation includes  resection/ bypass alone or
with  endoscopic, and  radiotherapy techniques. Non surgical procedure
include laser recannulization ,endoscopic dilation +/- stent placement.
Patients who undergo stent placement for obstruction  frequently take
solid foods  ,also don’t  require additional interventions.
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T reatment protocols: Treatment plans should be planned with
tumour board based on stage of disease, surgical fitness , the preference
of patient and his comorbidities
Stage 0 to IA
? Endoscopic mucosal resection / surgery is treatment of choice  early
stage gastric cancer; but  complete surgical resection gives long-term
survivial.
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Stage IB to IIIC, potentially resectable, medically fit
? Perioperative, neoadjuvant chemotherapy  / chemo radiotherapy
followed by surgery done
Stage IB to IIIC, potentially resectable, medically unfit
? Chemoradiotherapy or chemotherapy
Stage IV
? Chemotherapy for metastatic disease; local therapy is not indicated
NEOADJUVANT CHEMOTHERAPY:
? Paclitaxel DOSE  50 mg/m2 IV on day 1 ;carboplatin IV on day 1;
weekly for 5wk[3, 4] or
? Cisplatin 75-100 mg/m2 IV on day 1; 5-fluorouracil ( 750-1000
mg/m2/day IV continuous  on days 1-4 and 29-32 IN  single 35 day
cycle[6]or
? Cisplatin 30 mg/m2 IV on day 1 ; capecitabine 800 mg/m2 PO BID
on days 1-5; weekly for 5wk[7]
PERIOPERATIVE CHEMOTHERAPY:
Treatment IS 3 cycles PREOPERATIVELY  and 3 cycles
POSTOPERATIVELY,  for adenocarcinoma of the distal esophagus or
og junction.[1]
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? Epirubicin 50 mg/m2 IV on day 1 ; cisplatin 60 mg/m2 IV on day 1;5-
FU 200 mg/m2/day IV continuous  daily for days 1-21; every 21d
cycle 1-3 preoperatively and cycles 4-6 postoperatively[2
Postoperative Chemoradiotherapy Regimens
The postoperative chemoradiotherapy regimens include those for og
junction.
? Leucovorin 20 mg/m2 IVP  IS GIVEN on days 1-5 ;  5-FU 425
mg/m2 IVP daily on days 1-5; every 28d (cycles 1, 3, and 4 given
before and after radiation), for cycles 2 give leucovorin 20
mg/m2 IVP on days 1-4 and 31-33 plus  5-FU 400 mg/m2 IVP daily
on days 1-4; every 35d (cycle 2 given with radiation)
First-Line Chemotherapy for Metastatic or Locally AdvaNCED
CANCER
Stage IV
For HER2-NEU overexpressing adenocarcinomas[1] :
? Trastuzumab 8 mg/kg IV loading dose on day 1 of cycle 1, then 6
mg/kg IV; every 21d with chemotherapy[29] or
? Trastuzumab 6 mg/kg IV loading dose on day 1 of cycle 1, then 4
mg/kg IV every 14d with chemotherapy Preferred regimens[1]
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? Docetaxel 75 mg/m2 IV on day 1 plus  cisplatin 75 mg/m2 IV on day
1 plus 5-FU 1000 mg/m2/day continuous IV infusion on days 1-5;
every 28d[30]
Outcomes
5-year survival rates following  gastric cancer diagnosis are 10%
to 21%. .Patients who undergo R0 resection have a better prognosis.
Recurrence rates after gastrectomy is roughly around  40% to
80% . recurrences mostly occur within a span of  3 years. The local
failure rate is highest  ranging from 38% to 45%, whereas peritoneal
dissemination is an important aspect of failure occurring in 54% of
patients . Isolated distant metastases are rare cause most patients with
metastasis have locoregional recurrence as well. Locoregional
recurrence occurs at  anastomosis,  bed of tumour  and in  regional
nodes. Blood  spread  to many sites.
Surveillance
Systematic follow up is essential  cause most recurrences occur
within  3 years,  Follow-up should include a
1.complete history  clinical  examination thrice for  1st year,
then half yearly  for 2 years, and then yearly once  thereafter
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 Laboratory investigations, including  complete hemogram and LFTs is
obtained as clinically indicated. Many get chest x-rays as well as CT
abdomen and pelvis done as routine. Yearly endoscopy is considered in
patients who had subtotal resection
Her 2/neu
ERBB2, Which is  well known proto-oncogene, located at 17q12( long
arm of chromosome 17). HER2 derives its name based on the similarity
it shares in  structure of human epidermal growth factor receptor HER1.
cell line from  rodent glioblastoma ,  neural tumor type gives its name to
neu. ErbB-2 derives its name based on similarity to ErbB ,  Gene
cloning reveals HER2, Neu, and ErbB-2 are encoded by  same
orthologs.
Protein
 ErbB family consists of 4 plasma membrane-bound receptor tyrosine
kinases. All four contain
1. intracellular domain.
2. transmembrane domain,
3. extracellular ligand binding domain,
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Interactions occur with a multitude of signaling molecules thus exhibit
both ligand-dependent  and independent activity. HER2 , a well known
heterodimeriser ,is  the preferred  dimerisation form of other ErbB
receptors. Autophosphorylation  of tyrosine residues occur in the
cytoplasmic recpetors initiating various signaling pathways.
The other family members are
1.Epidermal growth factor receptor,
2. erbB-3  and
3. erbB-4.
Signal transduction
HER2 activates following pathways
1.protein kinase  activated by mitogen
2.phosphoinositide 3-kinase
3.phospholipase c
4.protein kinase c
5.Signal transducer and transcription activation
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In summary, her 2  promotes cell proliferation and opposes apoptosis
actively and therefore should be under strict regulations to prevent
tumorigenesis.
HER2 and cancer
Amplification or over-expression of the ERBB2 gene mainly occurs
in  breast cancers around 20%. It is strongly associated  poor
prognosis.[6] Over-expression also occurs in
1.ovarian,
2. stomach, and
3. uterine cancer,
HER2 is accompanied by gene GRB7 amplification, associated with
breast, testicular germ cell, gastroesophageal tumours.
 As stated the HER2 is identified in lot  of tumors of which some carry
point mutations in the her 2 sequence. Substitution  of  valine for
glutamic acid results in  dimerization of this protein with absent ligand.
Drugs targeting HER2
Monoclonal  antibody trastuzumab (Herceptin) tagets against her 2 and
effective only in    HER2  over-expressed cancers.  Trastuzumab  binds
to HER2 resulting in increase in p27, a proliferation inhibitor
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protein. Pertuzumab, also inhibits  HER2 and HER3 receptors, and also
approved by the FDA for  combination use  with trastuzumab.
 NeuVax , immunotherapy based on peptide  drives T cells to
target and destroy cancer cells with HER2 over expression..
The expression of HER2 is being regulated in order estrogen
receptors signalling. Estradiol   and tamoxifen , causes  estrogen
receptor down-regulate HER2 expression.. However, when the ratio of
the coactivator  AIB-3 is greater than that of the corepressor PAX2, the
expression of HER2 is upregulated in the presence of tamoxifen, which
results in  tamoxifen-resistant breast cancer.
Recent evidence shows HER2 signaling in responsible for
resistance to the EGFR-targeted cancer drug cetuximab.
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MATERIALS AND METHODS:
Our hospital is a referral centre for gastro intestinal diseases with
attached institute of surgical gastroenterology. Cases  of carcinoma
stomach were selected randomly from from 2012 -2013:
1. Dept. Of general surgery( all 7 units)
2. Dept . of surgical gastroenterology
3.  Dept . of medical oncology
4.  Dept . of medical gastroenterology
5. Endoscopy clinic.
Samples were either in the form of endoscopy biopsy or
gastrectomy specimens.
Samples were collected after obtaining consent from the patient
and transported to pathology lab via formalin or saline containers and
tissue processing.
The patients were given full knowledge of the study and
explained its merits and demerits and obtained consent from them.
Tissues were mounted on paraffin blocks . then paraffin blocks
were used for slide preparation one for routne histopathology thus
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determining its staging , grading and margin positivity whenever
possible.
The other slide is prepared for immunohistochemistry and
subjected to immunohistochemistry. A thorough history and clinical
examination obtained from the patient and evaluation done.
IMMUNOHISTOCHEMISTRY:
Immunohistochemistry  is a golden method to demonstrate
presence and  proteins location  in tissues by staining..
Immunohistochemical staining is based on antibodies which
recognize the target protein. The  antibody binds only to  protein of
interest in the tissues as they are highly specific. The antibody-antigen
interaction is  seen by  chromogenic technique  in which an  conjugation
of enzyme to antibody  cleaves  substrate producimg  colored precipitate
at  location of  protein
IHC-P refers to staining of  fixed tissues  and paraffin embedded
before  sectioning. The basic steps of  IHC-P protocol are :
 1.  tissue  fix and embedding
2.  section cut and mount
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3. removal of paraffin & rehydration  of  section
4. antigen retrieving
5. Immuno histo chemical stain
6. Counter stains
7. Dehydration  and  mount stabilising
8.microscopic examination
 A. Optimisation of new  Ab
 1.  retrieval  of Ag
 2.  concentration  of 1* Ab
 3. Detecting
 B. Fixing
C. paraffin removal
 D.  Ag retrieving
 1. Buffer solutions -epitope retrieval
 2. epitope retrieving methods
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 3. retrieving of Ag by enzymes
 E. Immunohistochemical staining
 1.  guidelines
 2. Protocols
 3. Control
 4.  amplification of signal
 F. Resource
G. Additional buffers  primary and secondary reagents are obtained
from the company “Thermo” and the slides used were chrome alum
slides and various reagents were used.
Then the slides were observed under light microscopy  and they
were graded as 1+ , 2+ and 3+ based on positivity. Since the facility of
fluorescent in situ hybridisation not available in our hospital, it is not
done.
Table 1 – Classification of HER2/NEU expression determined by
THERMO ) immunochemical method.
SCORE Expression Staining Pattern
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0 means  Negative  or No staining , or membrane staining is
<10% of tumor cells.
1+ Negative A faint  perceptive membrane staining  detected >
10% of  tumor cells. Cells are only stained in part of  membrane.
2+ Positive  weak  complete membrane stain observed in 10% of
tumor cells.
3+ Positive  strong complete membrane stain observed in >10%
of the tumor cells.
The evaluation of carcinoma stomach in our institution follows a
protocol;
a. All patients presenting  to op with  vomiting/
dysphagia/melena /hematemsis/ loos of weight and appetite
are subjected to thorough history and clinical examination
and subejected to endocopy examination.
b. All patients presenting with abdominal pain and dyspepsia
above the age of 40 years is subjected to the same and
endoscopy is done as an extension of clinical examination
c. Those who are less than 40 years with abdomen pain and
dyspepsia, if not resolved after initial treatment are
subjected to endoscopy.
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d. Those who are diagnosed to have endoscopic findings of
malignancy are admitted to ward and evaluated thoroughly
e. We employ a technique of multiple biopsies from the
lesion. A minimum of six bits of specimen is taken and sent
for histopathological examination
f.  A complete blood count, renal function tests , liver
function tests, chest x ray, and ecg are obtained for the
patient.
g. Pre operative planning done for the patient
h. Usg of the abdomen isdone as a screening procedure. If it
shows any signs of metastasis, patients are subjected to
palliative treatment
i. If usg shows no sighns of metastasis, CECT ABDOMEN
is done to stage the disease if CECT also rules out
metastasis,
j. A diagnostic laparoscopy is done to look for surface
metastasis, peritoneal metastasis , subcentimetric metastasis
k. If all rules out out malignancy, pt is proceeded with surgery
l. A minimum of subtotal or total gastrectomy with D 2
lymphadenectomy is done as a curative procedure. And the
specimen is subjected to histopathological examination
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revealing the the tumour grading , staging , margins and
lymphnode status and subjected to her 2/neu IHC.
m.  If it is not operable, then a palliative procedure is attepted
if the patients presents with obstruction, or else, patient is
given chemotherapy as palliation
n. All patients who underwent surgery are subjected to
adjuvant chemotherapy and followed up regularly.
TOTAL POPULATION:
50 CASES
INCLUSION CRITERIA: :
A. All cases of gastric and gastro oesophageal junction
adenocarcinomas
B. Patients who are under follow up for a minimum period of six
years.
EXCLUSION CRITERIA:
A. The  tumours of stomach other than adenocarcinoma
B. Esophageal malignancies
C. Those who don’t come for follow up.
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RESULTS:
A TOTAL population of 50 cases were studied for her 2 /neu. The
results od the study will be discussed as follows:
In our study ofgastric adenocarcinoma cases, there was a male
preponderance. Male- 39 and female 11 and thus incidence of 78% and
22 % respectively. The results are depicted as in table 1
male female
cases 39 11
Table 1.gender distribution
Chart  1: gender distribution
cases of carcinoma stomach
male
female
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The age distribution distribution varies from 20 years to 82 years.
But the peak distribution of cases were in the sixth and seventh decades
30% and 34% respectively. In females the ae distribution curve doesn’t
show any peaks and the incidence remains the same in almost all age
groups, but in males the age incidence gradually raises as described in
table 2.
The mean age  of presentation is calculated to be 53. Even though
,it is a disease of old age, cases so young like 20 years of age are
reported.
chart  2. age distribution curve
In our study, we found that there is a high incidence of  antral
carcinomas than proximal gastric unit cancers. Antral  carcinomas are
found to contribute to 48% of all gastric carcinomas. (Table  3)
0
2
4
6
8
10
12
14
16
18
AGE 20-29 30-39 40-49 50-59 60-69 70&
ABOVE
MALE
FEMALE
59
Based on locality, the incidence of  gastric adenocarcinomas are as
follows:
1. OG JUNCTION TUMOURS-16%-8 cases
2. FUNDUS-8%-4 cases
3. BODY-22%-11 cases
4. ANTRUM 48%-24 cases
A special entity of stump carcinomas arising from gastrojejunal
stomas  are found to contribute 6% of all gastric adenoarcinomas.
Chart  3. location of tumours and incidence.
Endoscopy was done for all cases and the findings as seen on
endoscopy are as follows:
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Most of them were with ulceroproliferative tumours by endoscopy.
Some were found to be ulcerative like gastric ulcers . and polypoid
growths  were also found on endoscopy. Only one case of schirrous
carcinoma was  seen.  (Table 4)
According to Bormann classification, the proportion of cases  to
be seen as in endoscopy findings are:
1. Type 1- 18%
2. Type 2-2%
3. Type 3-78%
4. Type 4-2%
Those cases which were operated , morphological comparison
also has been correlating to findings on endoscopy.
BORMANN CLASSIFICATION
POLYPOID
FUNGATING
ULCERATIVE
DIFFUSELY INFILTRATIVE
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chart 4. Bormann classification proportion of cases.
Histopathological examination of the cases were done and the
level of differentitation were noted and the results were as follows:
Dividing into two broad categories according to Lauren classification, it
is divided as
a. Intestinal
b. Diffuse variety
Intestinal variety included both well and moderately differentiated
carcinomas which are found to show some degree of gland formation
and found  to be occurring in equal proportions to diffuse variety.
Diffuse variety included poorly differentiated and signet ring cell
carcinomas were also existing equally.- 50%
Table 2. case distribution based on laurens classification
male female
intestinal 19 6
Diffuse 20 5
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Chart 5. Laurens classification
Based on the degree of differentiation, poorly differentiated
carcinomas were majority contributing to 50 % of cases. Well
differentiated carcinomas were not common contributing to only 12%
and moderately differentiated carcinomas was found to be 38%.( Table
6)male and female cases are proportionate according to gender
distribution.
Table 3. case distribution based on differentiation
WDC MDC PDC
male 5 14 20
female 1 5 5
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Chart 6. . case distribution based on differentiation
In our study we found that 30% of tumours were metastatic at the
time of presentation.( table 7) We also found of the 15 cases found to be
metatstatic, 11 are identified  primarily by radio imaging techniques like
USG abdomen and CECT abdomen and 4 cases (25%) which  were
found to be negative for metastasis  were proven to be malignant by
diagnostic laparoscopy.( Table 8)
We practice diagnostic laparoscopy as a protocol for those cases
who were found to be negative for metastatic disease by radiological
imaging.
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Chart 7.case proportion based on metastasis
Table 4.case proportion based on metastasis.
imaging D -lap
metastasis 11 4
CASES
METASTATIC
NON METASTATIC
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Chart  8> metastasis identification techniques
In our study, we found the clinical staging presenting to us were as
follows;
Stage 1 Stage 2 Stage 3 Stage 4
cases 1 19 16 15
Table 5. staging proportion
METASTASIS
IMAGING
DIAGNOSTIC LAPAROSCOPY
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Chart .9 case distribution according to staging.
Stage  1: 1 case – 2%
Stage 2: 19 cases-38%
Stage 3: 16 cases-32%
Stage 4: 15 cases -30%
In our study , most carcinomas were found to be in stage 2 followed by
stage 3. Hence most carcinomas were operable
About the treatment  given , subtotal gastrectomy was the most common
treatment offered contributing  to 36 % ( 18 cases).the various
treatments offered are(:table 10)
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a. Subtotal gastrectomy 18 cases -36%
b. Total gatrectomy  11 cases- 22%
c. Anterior gastrojejunostomy with jejunostomy 9 cases
– 18%
d. Feeding  jejunostomy  12 cases -24%
Chart  10.treatment offered
All cases were given chemotherapy . the subdivisions are:
a. adjuvant chemotherapy 28 cases-56%
b. neoadjuvant chemotherapy- 7cases -14%
c. palliative chemotherapy- 15 cases-30%
SURGERIES
SUBTOTAL GASTRECTOMY
TOTAL GASTRECTOMY
ANTERIOR
GASTROJEJUNOSTOMY WITH
JEJUNOJEJUNOSTOMY
FEEDING JEJUNOSTOMY
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Neoadjuvant chemotherapy was offered for non metastatic
patients but inoperable patients to downstage the  disease
Chart  11. Chemotherapy offered
The results of immunohistochemistry for HER2/neu protein over
expression  is as follows(:table 12)
3 cases came as positive for HER/neu- 6% positive
47 cases came as negative for HER2/neu- 94% negative
CHEMOTHERAAPY
PALLIATIVE
ADJUVANT
NEOADJUVANT
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pic. Her 2/neu positivity- membrane staining > 10% of cells
A strong positive in a case of poorly differentiated carcinoma . pic
shows staining of membranes more than 10 % of cells.
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pic. Her 2/neu positivity
All  the three positive cases were poorly differentiated
carcinomas.
Table 12. HER2/NEU POSITIVITY
Her2/neu +ve -ve
cases 3 47
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ALL THE THREE patients were male above 50 years.
All the three positive cases were poorly differentiated adenocarcinomas.
Two of them were arising OG JUNCTION AND CARDIA and the other
from ANTRUM.
Two had ulceroproliferative growth and one had polypoid growth on
endoscopy.
One presented with metastatic disease and all the three presented with
serosal disease.
HER2/NEU
positive
negative
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Table 13..her 2/neu and differentiation of tumours
Thus 12% of poorly differentiated adenocarcinomas were positive
for her 2 /neu.
Results also show 25 % of OG junction carcinomas( 2/8) were
her2/neu positive
About 10 % of carcinomas presenting with stage 3 and 4 disease
are found to be positive for HER2/NEU.
Of the 2 positive cases in stage 3, who were offered, neoadjuvant
chemotherapy responded poorly and subsequently developed metastasis
during follow up.
cases
wdc
mdc
pdc + ve for her 2/neu
pdc -ve for her2/neu
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In all 3 positive CURATIVE surgery could not be attempted either
owing to metastasis or inoperability
Table14. her 2/neu status comparison
Table 15. proportion of positive cases in advanced gastric malignancies
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DISCUSSION
Sex difference with male preponderance is correlating with others
studies owing to risk factors such as smoking and drinkind are common
among males. Gastric adeno carcinoma even thogh it is a disease of the
6th and seventh decade , occurred at even young age of 20 years. A.Ieni
and his colleagues studied the incidence of her2/neu in gastric
carcinoma patients. The mean age in their study 68.3 years and the
youngest incidence was 41 years{A.IENI, 2013 #2}. But our study
reveals the mean age to be a decade less than Sicilian study. Antral
carcinomas are common which could be explained by association with
H.pylori infection.
Most of the carcinomas were ulceroproliferative on endoscopy.
The  histological type was correlating as diffusetype  contributing
almost 50 % of the cases in our study as in a study by Fernando and
colleagues{CIRNE-LIMA, 2009 #4}.
But coming to the histopathological grading, again poorly
differentiated carcinomas were common in our population contributing
50 % , but the rates were very high in Brazilian study{CIRNE-LIMA,
2009 #4}, as .91%..
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Many  stud ies have already  documented HER2 amplification in
gastric carcinoma, but association with  survival or TNM status of
patients is still debatable . Giuffrè et al  encountered a HER2
overexpression rate of 21.10% in a small population done by a single
pathological unit (16), and found  consistent with the results that is
reported elsewhere in the literature (11,19,21,25-28), in which the mean
HER2 positivity rate, was 19.2% (range, 7.1-42.6%) (25) . In   our
study,  a population from a single hospital of 50 cases  and IHC done by
a single pathological unit,HER2 overexpression was identified in 3 (6%)
of  50 samples . This  rate is much lower than the mean HER2 positivity
that is previously cited (25). The incidence rate is still low  taking into
consideration only the IHC studies  available in the literature, which is
performed on 3264 AGC samples (25), the mean HER2-positive rate
was 17.6% (range, 6.8-34.0%). In our population the incidence is on
lower range. But in the study by Sekaran et al on Indian population, they
reported a higher incidence of 44 %, but they didn’t find any
clinicopathological correlation. In 2008, a study from Switzerland
reported 4.9% her-2/neu positivity by immunohistochemistry12The
variability of her  2/neu  studies in gastric cancer is  explained either by
genetic variations between different tumours or by  diagnostic facility
available. The most reliable results are from methods at protein level
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detection (RT-PCR, FISH, quantitative PCR), but costs turn them
unavailable for broader use in our hospital. Uchino16 detected 2%
positive staining of  HER2/NEU  protein in poorly differentiated gastric
carcinomas where as in our study it is found to be 6%, and Tsujimoto17
found no amplification of HER2/NEU  gene in undifferentiated type
carcinoma  by Western Blot. But in our study we found HER2/NEU
expression only in poorly differentiated carcinomas .
It is reported that HER2/ neu gene amplification is more common in
gastroesophageal Junction carcinomas with positive rate of 24%- 32%,
which is more than that (9.5% 18%) of other parts of  stomach and  the
related mechanism remains unclear. In our study,the rate of HER2/ neu
gene amplification in  patients with primary cancer in OG junction is
25% ( p< 0.05)correlating to previous reports compared to other parts of
stomach.
In most studies, reports say  that HER2/neu gene amplification
and protein overexpression in gastric cancer does not with
clinicopathologic parameters such as depth of tumor,  invasion and
lymph node metastasis, but were associated with the the poor prognosis
of patients.  But   in our study, we found that all the three cases were in
either stage 3 or stage 4. One case had a metastatic presentation and the
other two had a serosal disease infiltrating to adjacent structures.
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Becker18and Kameda et al.19 described as no  Her-2/Neu gene
amplification was found in diffuse type gastric cancer and they found
20% of amplification in intestinal type.  Correlation is high between
HER2 expression - intestinal  type had been  reported by many  authors
in late 20 the century . In  Finnish study,associtation of her2/neu
amplification with poor carcinoma-specific survival is strong
particularly more  in  intestinal type subgroup of cancers , but the
contradicting fact  is it should  have better prognosis than  diffuse type
of gastric carcinoma.[45]  the same also reported in a Korean
study.[30] Finally, in  ToGA trial, HER2 positivity varied  by histological
subtype (intestinal 34%, diffuse 6%, mixed 20%). But in our study we
found no HER2/NEU positivity in intestinal type of adenocarcinomas
and we found only in diffuse type carcinomas (p<0.05). All the three
had a poor prognosis and two did not respond for chemotherapy as well.
FISH and trastuzumab were not available in our institution, hence we
were not able to study the response to herceptin in these patients.
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CONCLUSION
There is a low prevalence of  HER2/NEU positivity 6% in the
population of gastric carcinoma patients studied. The low incidence can
be explained by the difference in genetics in gepgraphical population or
due to the diagnostic facility available. FISH could have helped more in
identifying more positive cases.
HER2/neu positivity occurred more in OG junction tumours 25%
and hence can be used as prognostic indicator for OGJunction subtype
cancers . The  positivity for HER2/neu also indicates advanced gastric
carcinoma and poor prognosis and occurred mostly in poorly
differentiated  diffuse carcinomas contradicting to previous studies
published.
This could be explained either as a result of small population
studied or diagnostic facility availability. However, studies on larger
population with hybridisation techniques is essential so that we could
add more years to patients with poor prognosis and improve the quality
of life.
In a developing country like India, where use of trastuzumab
should be cost effective for our patients, more studies are warranted in
this area, so as to get the broader picture of the same.
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PROFORMA
A.NAME:
B.AGE
C.SEX:
D.IP.NO:
E.DATE OF ADMISSION:
F.DATE OF SURGERY:
G.DATE OF DISCHARGE:
H. HISTORY OF PRESENTING ILLNESS:
1.H/O DYSPEPSIA AND DYSPHAGIA
2.    H/O ABDOMEN PAIN:
? SITE
? ONSET
? PROGRESSION
? RADIATION
? TYPE
86
? AGGRAVATING/RELIEVING FACTORS
3.H/O VOMITTING
4. H/O HEMATEMESIS
5. H/O LOSS OF WEIGHT  AND LOSS OF APPETITE
6.  H/O JAUNDICE
7.H/O MELENA
I.PAST HISTORY:
    H/O DM/SHT/ASTHMA/TB/EPILEPSY/IHD
    H/O PREVIOUS SIMILAR/MEDICAL/SURGICAL ILLNESS
J.PERSONAL HISTORY:
      H/O INTAKE OF SALTY FISH, SMOKED FOOD
     H/O DRUG INTAKE
     H/O SMOKING OR ALCOHOLIC
K.FAMILY HISTORY:
L.CLINICAL EXAMINATION:
87
M.GENERAL EXAMINATION
N.SYSTEMIC EXAMINATION:
? CVS:
?  RS:
? PER ABDOMEN:
CNS:
O: CLINICAL DIAGNOSIS
INVESTIGATIONS:
P. ENDOSCOPY AND BIOPSY:
SITE:
1. OG JUNCTION
2. FUNDUS
3. BODY
4. ANTRUM
5. GJ STOMA
Q . HER 2/NEU EXPRESSION IN BIOPSY
R .CECT ABDOMEN
88
S. ROUTINE INVESTIGATIONS:
T. DIAGNOSTIC LAPAROSCOPY
U. STAGING
V. TREATMENT
W. COMPLICATIONS
X. CHEMOTHERAPY
Y. COMPLICATIONS
Z.  FOLLOW UP



NAME AGE SEX IP.NO PRE.COMP LOCATION
BORMAN
N
TYPE
LAUREN
TYPE HISTOLOGY
 IMAGING
FOR MET
D-LAP-
SURFACE
METS OPERABILITYSTAGING TREATMENTCHEMO
HER 2/
NEU
STATUS
ARUMUGAM 60 M 35324 2 BODY 3 DIFFUSE PDC P FOUR FJ PALLIATIVE NEGATIVE
GOPINATH 60 M 44639 3 ANTRUM 2 DIFFUSE PDC N P FOUR AGJ PALLIATIVE NEGATIVE
RAMALINGAM 50 M 87949 1,2 ANTRUM 3 DIFFUSE PDC N N P TWO SUBTOTAL ADJUVANT NEGATIVE
DEIVANAYAGI 35 F 47567 1,2 GJ STOMA 1 DIFFUSE PDC P FOUR FJ PALLIATIVE NEGATIVE
LALITHA 29 F 40796 2,5 BODY 1 DIFFUSE PDC N N P THREE TOTAL ADJUVANT NEGATIVE
SELVAKUMAR 20 M 44588 1,5 OGJ,FUNDUS 3 DIFFUSE PDC P FOUR FJ PALLIATIVE NEGATIVE
PRATHESH 23 M 51822 2,3 BODY, ANTRUM 3 DIFFUSE PDC N N P THREE TOTAL ADJUVANT NEGATIVE
MOHAMMAD 65 M 3277 3 GJ STOMA 3 DIFFUSE PDC P FOUR FJ PALLIATIVE NEGATIVE
JAGANATHAN 70 M 50624 1 OGJ 1 DIFFUSE PDC N N N THREE FJ NEOADJUVANTPOSITIVE
RAVICHANDRAN43 M 7395 2,3 ANTRUM 3 DIFFUSE PDC N N P TWO SUBTOTAL ADJUVANT NEGATIVE
RAGAVAIYAH 60 M 13740 3,5 GJ STOMA 3 DIFFUSE PDC N N N THREE TOTAL ADJUVANT NEGATIVE
MOORTHY 52 M 33739 1 ANTRUM 3 INTESTINALMDC N N P TWO SUBTOTAL ADJUVANT NEGATIVE
SELVAM 51 M 36815 1 ANTRUM 3 DIFFUSE PDC N P N FOUR AGJ PALLIATIVE NEGATIVE
RAJ 70 M 30573 2,3 ANTRUM 3 DIFFUSE PDC P FOUR AGJ PALLIATIVE POSITIVE
RANGANATHAN82 M 41469 1,2 BODY, FUNDUS 4 DIFFUSE PDC P FOUR FJ PALLIATIVE NEGATIVE
RANI 43 F 53817 1,5 FUNDUS 3 DIFFUSE PDC P FOUR FJ PALLIATIVE NEGATIVE
RAJI 53 M 8072 2,3 BODY 3 DIFFUSE PDC P FOUR FJ PALLIATIVE NEGATIVE
DURAI 55 M 7694 2,3 BODY,FUNDUS 1 DIFFUSE PDC N N P TWO SUBTOTAL ADJUVANT NEGATIVE
NARASIMMAH 49 M 15768 2,3 ANTRUM 1 INTESTINALMDC N N P TWO SUBTOTAL ADJUVANT NEGATIVE
JAIGANESAN 60 M 2108 2,3 ANTRUM 3 INTESTINALMDC N N P TWO SUBTOTAL ADJUVANT NEGATIVE
SHEIK ALAUDDIN63 M 55817 2,5 OGJ, FUNDUS, BODY 1 INTESTINALMDC N N P THREE TOTAL ADJUVANT NEGATIVE
PREMA 36 F 35470 2,3 ANTRUM 3 INTESTINALMDC N N P TWO SUBTOTAL ADJUVANT NEGATIVE
MARIMUTHU 65 M 5674 1,5 OGJ 3 INTESTINALMDC N N P TWO TOTAL ADJUVANT NEGATIVE
DILLI 70 M 5796 2,3 ANTRUM 3 INTESTINALMDC N P N FOUR AGJ PALLIATIVE NEGATIVE
KALLIAPPAN 78 M 5474 2,3 BODY,ANTRUM 3 INTESTINALWDC N N P ONE TOTAL ADJUVANT NEGATIVE
MARIMUTHU 33 M 53000 2,3,5 BODY 3 INTESTINALMDC N N P TWO TOTAL ADJUVANT NEGATIVE
PATTAMMAL 65 F 55174 2,3 ANTRUM 3 INTESTINALMDC N N P TWO SUBTOTAL ADJUVANT NEGATIVE
AMMAIYAPPAN55 M 21796 2,3,5 ANTRUM 3 INTESTINALMDC N N P THREE TOTAL ADJUVANT NEGATIVE
MASTER  CHART
ARUMUGAM 53 M 36851 1,5 OG 3 DIFFUSE PDC N N N FOUR FJ ADJUVANT POSITIVE
ANANDHAN 41 M 39059 2,3 ANTRUM 2 DIFFUSE PDC N N P TWO SUBTOTAL ADJUVANT NEGATIVE
MOHAN 52 M 39214 3,5 ANTRUM 3 INTESTINALMDC N N P TWO SUBTOTAL ADJUVANT NEGATIVE
KANNIYAPPAN 58 M 40369 2,3 ANTRUM 3 INTESTINALWDC N N P TWO SUBTOTAL ADJUVANT NEGATIVE
SHANMUGAM 50 M 39529 3,5 ANTRUM 1 INTESTINALWDC N N P TWO SUBTOTAL ADJUVANT NEGATIVE
MARIMUTHU 45 M 39000 3,5 ANTRUM 1 DIFFUSE PDC P FOUR AGJ PALLIATIVE NEGATIVE
SELVI 32 F 35202 3,5 BODY 1 DIFFUSE PDC N N P THREE TOTAL ADJUVANT NEGATIVE
KRISHNA 53 M 37747 1,2 OGJ 3 INTESTINALWDC N N P TWO TOTAL ADJUVANT NEGATIVE
MANNAMMAL 55 F 30423 4 ANTRUM 3 INTESTINALMDC N N P TWO SUBTOTAL ADJUVANT NEGATIVE
GANGAN 70 M 32379 1,2 OGJ 3 INTESTINALMDC N N N THREE FJ ADJUVANT NEGATIVE
NANGOORAN 53 M 31781 2,3 ANTRUM 3 INTESTINALMDC N P N THREE AGJ ADJUVANT NEGATIVE
LOGANATHAN 65 M 30714 2,3 ANTRUM 3 DIFFUSE PDC N N P THREE SUBTOTAL ADJUVANT NEGATIVE
DHANALAKSHMI58 F 28328 2,3 3,4 3 INTESTINALWDC N N P TWO SUBTOTAL ADJUVANT NEGATIVE
PADMAVATHY 43 F 29578 2,3 ANTRUM 3 INTESTINALMDC P FOUR AGJ PALLIATIVE NEGATIVE
MURUGAN 61 M 29004 1,5 OGJ 3 INTESTINALMDC N N N FOUR FJ PALLIATIVE NEGATIVE
SELVANATHAN 40 M 26818 2,3 BODY 3 DIFFUSE PDC N N N FOUR SUBTOTAL ADJUVANT NEGATIVE
AARON 55 M 25052 1,2,3 FUNDUS,BODY 3 DIFFUSE PDC N N N FOUR TOTAL ADJUVANT NEGATIVE
ISMAIL 70 M 24897 2,3 ANTRUM 3 INTESTINALWDC N N N FOUR AGJ ADJUVANT NEGATIVE
MYMOON 29 F 27083 2,3 BODY 3 INTESTINALMDC N N P TWO SUBTOTAL ADJUVANT NEGATIVE
NAGABHUSANAM53 F 26831 2,3 BODY,ANTRUM 3 DIFFUSE PDC P FOUR AGJ PALLIATIVE NEGATIVE
SHANMUGAM 62 M 22968 1,2 FUNDUS,BODY 3 INTESTINALMDC N N N FOUR FJ NEOADJUVANTNEGATIVE
ALLASAMY 65 M 25707 2,3 ANTRUM 3 INTESTINALMDC N N P THREE SUBTOTAL ADJUVANT NEGATIVE
